Dianthus Therapeutics, Inc. · NASDAQ:DNTH
Dianthus Therapeutics — Corporate Update (March 2026)
22 slides from Dianthus Therapeutics's corporate update, Mar 9, 2026
Slide 1: Early GO Decision in CAPTIVATE CIDP Trial
Dianthus Therapeutics Early GO Decision in CAPTIVATE CIDP Trial March 9, 2026 Exhibit 99.3
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities
Slide 3: Agenda
Agenda Introduction Marino Garcia, Chief Executive Officer Early GO Decision in CAPTIVATE Simrat Randhawa, MD, Head of Research & Development Closing Remarks Marino Garcia, Chief Executive Officer Analyst Q&A Marino Garcia, Chief Executive Officer Simrat Randhawa, MD, Head of Research & Development
Slide 4: Introduction
Introduction Marino Garcia, CEO
Slide 5: Interim Responder Analysis in CAPTIVATE planned with first 40 patients
Interim Responder Analysis in CAPTIVATE was planned with first 40 patients completing Open-Label Part A Claseprubart 300mg/2mL S.C. Q2W (N=64) Placebo (N=64) Claseprubart 600mg/4mL S.C. Q2W (N=64) Screen PART A: Up to 13-Week Open-Label Claseprubart Only PART B: 52-Week Pbo- controlled RCT CIDP diag
Slide 6: Significant differences between CAPTIVATE and ADHERE
Significant differences between CAPTIVATE and ADHERE Source: Company filings, presentations and clinicaltrials.gov. Ig refers to IVIg and SCIg Data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-tr
Slide 7: Active C1s inhibition with riliprubart has demonstrated clinical proof-of-concept
Active C1s inhibition with riliprubart has demonstrated clinical proof-of-concept across broad patient groups Claseprubart is being evaluated with a convenient, low volume dose of 300mg/2mL Q2W Riliprubart Phase 2 at PNS 2024 Based on riliprubart patent filing (Pg 76) Ph. 2 Riliprubart Data in Activ
Slide 8: Targeting response rate of >50% out of first 40 participants
Targeting response rate of >50% (>20 responders) out of first 40 participants to complete Part A GO: However, increase dose as responder rate below precedent Less than 20 Responders 25% 30% 45% 55% 60% 65% 70% 75% 20 or More Responders Data from CAPTIVATE and riliprubart Ph. 2 are derived from diffe
Slide 9: Early GO Decision in CAPTIVATE
Early GO Decision in CAPTIVATE Simrat Randhawa, MD, Head of Research & Development
Slide 10: Early GO decision reached with less than planned participants completing Part A
Early GO decision reached with less than 40 planned participants completing Part A GO decision reached early after 20 confirmed responders were achieved with less than 40 planned participants completing Part A Independent DSMB reviewed the data to date and confirmed GO decision; no related serious i
Slide 11: CAPTIVATE Part A baseline patient characteristics similar to precedent aC1s Ph. 2
CAPTIVATE Part A baseline patient group characteristics are similar to precedent aC1s Ph. 2 study1 Broad representation of patients across North America, Europe, and Asia in CAPTIVATE Part A Data from CAPTIVATE and riliprubart Ph. 2 are derived from different clinical trials conducted at different t
Slide 12: Early responder rates support 300mg/2mL Q2W dose and trial design updates
Early responder rates support 300mg/2mL Q2W dose and updates to CAPTIVATE Trial Design Element Original Design Anticipated New Design Claseprubart CAPTIVATE Implications Part A Dose 300mg/2mL S.C. Q2W 300mg/2mL S.C. Q2W No change to Part A dose given results observed to date Study Arms in Part B 300
Slide 13: Revised CAPTIVATE study design going forward
PART B: 52-Week Pbo- controlled RCT Revised CAPTIVATE study design going forward Claseprubart 300mg/2mL S.C. Q2W (N=64) Placebo (N=64) Screen PART A: Up to 13-Week Open-Label Claseprubart Only CIDP diagnosis confirmed by an Independent CIDP Review Panel (ICRP) Open-Label Extension: 104 Weeks Loading
Slide 14: Closing Remarks
Closing Remarks Marino Garcia, CEO
Slide 15: Today's update continues to build on the promise of claseprubart
Today’s update continues to build on the promise of claseprubart to be a potential pipeline-in-a-product and best-in-class therapy in growing and underserved markets CAPTIVATE Part A Early GO Decision in CIDP Ph.2 MaGic Showed Rapid & Robust Improvements in gMG Q3’25 Q1’26
Slide 16: US CIDP market offers substantial growth potential given high unmet need
US CIDP market offers substantial growth potential given high unmet need and limitations of current standard of care Opportunity for an active C1s inhibitor with the target profile of claseprubart to replace the standard of care Current Ig and biologics account for >$3.5B5,6 Despite SoC, many (30-50
Slide 17: Survey of US Neurologists supports opportunity in CIDP
Survey of US Neurologists supports potential transformative opportunity in CIDP of Neurologists strongly prefer treatment options without a boxed warning or REMS program ~54% Total Neurologists 80 Neuromuscular Specialist 81% Generalist 19% Academic 58% Community based 42% Sample Demographics ~13 ye
Slide 18: Surveyed Neurologists want safer, more effective, convenient options than IVIg
% of Surveyed Neurologists Who Strongly Believe… Surveyed Neurologists want safer, more effective and convenient treatment options than IVIg for CIDP patients Significant unmet need for effective therapies for patients who don’t respond to IVIg 75% IVIg imposes a high treatment burden due to frequen
Slide 19: Achieving this target profile could position claseprubart as a potential blockbuster
Achieving this target profile could position claseprubart as a potential blockbuster treatment for CIDP Improvement over SoC (i.e. Ig) with continuous, effective symptom control C1s SAFETY (Enjaymo) EFFICACY (IVIg/SCIg) AUTOINJECTOR CONVENIENCE (DUPIXENT) Comparable safety to FDA-approved C1s & Clas
Slide 20: Claseprubart opportunity in three large and growing US neuromuscular markets
Claseprubart has opportunity to compete as a potential 1L biologic in three large and growing US neuromuscular markets >100K patients >140K patients >150K patients AChR+ gMG patients Positive Ph. 2 data reported Sept. ’25 >40K CIDP patients Early GO decision announced Mar. ‘26 Ph. 2 top-line data ex
Slide 21: Advancing a leading autoimmune-focused biotech with two clinical stage programs
Advancing a leading autoimmune-focused biotech with two clinical stage programs Program Indication Ph. 1 Ph. 2 Ph. 3 Upcoming Milestones Claseprubart aC1s gMG >100,000 U.S. Patients Initiation of Ph. 3 study expected in mid-26 Ph. 3 top-line results expected in 2H’28 CIDP >40,000 U.S. Patients Part
Slide 22: Q&A
Q&A Early GO Decision in CAPTIVATE CIDP Trial March 9, 2026
Dianthus Therapeutics — Corporate Update (March 2026) on 6ix